Improving Care for Rural Patients With Solid Tumors

Launched by UNIVERSITY OF COLORADO, DENVER · Jun 1, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Improving Care for Rural Patients With Solid Tumors," is focused on helping patients with various types of solid tumors, including lung, head and neck, thyroid, cervical, breast, bladder, colon, and rectal cancers, who live in rural areas. The study is testing a program called CARES (Cancer Advocacy, Resources, Education, and Support) to see if it can help patients start their cancer treatment sooner after diagnosis and complete their treatment on time.

To participate, individuals must be adults over 18 who speak English or Spanish and are receiving cancer treatment at specific hospitals in Colorado. They should also live in certain rural counties and have been diagnosed with one of the specified cancers. Participants can expect to be part of a supportive program that aims to improve their treatment experience. It's important to note that the study is currently recruiting participants, and it excludes individuals under 18 or those who do not meet the language or treatment criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria Assessed During Screening:
• • 1. Provision to sign and date the consent form.
• • 2. Stated willingness to comply with all study procedures and be available for the duration of the study.
• • 3. Male and female adults over 18 years old
• • 4. English or Spanish speaking
• • 5. Receives cancer treatment at UCH- Aurora, UCH-Highlands Ranch, UCHealth North, UCHealth South- UCHealth Memorial Hospital, UCHealth Parkview Hospital, San Juan Cancer Center, RMCC-Pueblo, SCL-St. Mary's, or Parkview Medical Center.
• • 6. Resides in any of the rural counties served by the UCH-Aurora, UCH-Highlands Ranch, UCHealth North, UCHealth South- UCHealth Memorial Hospital, UCHealth Parkview Hospital, San Juan Cancer Center, RMCC-Pueblo, SCL-St. Mary's, or Parkview Medical Center with Rural-Urban Continuum Codes (RUCC) codes 4-9.
• • 7. Diagnosed with lung cancer (LC): small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), using incident LC diagnosis according to the International Classification of Diseases for Oncology \[ICD-O\] codes: C34.0, C34.1, C34.2, C34.3, C34.8, C34.9, and C33.9, and other lung cancer variants
• • 8. Stage of diagnosis for SCLC (limited vs. extensive), NSCLC (Stages 0, I, II, IIA, IIIB, IV), according to the American Joint Committee on Cancer Staging \[AJCC\] Tumor Node Metastasis \[TNM\] stages: I-IV)
• • 9. Will receive the following types of breast, bladder, cervix, colon, rectum, lung, head-and-neck cancer treatments (surgery, radiation therapy, chemotherapy, or a combination of those modalities, including neoadjuvant and adjuvant therapy)
• • 10. Diagnosed with head and neck cancer (HNC) using head and neck squamous cell carcinoma (HNSCC) ICD-O codes for the oral cavity (including lip; codes C00.0-C00.6, C00.8, C00.9, C02.0-C02.3, C02.8, C0.2.9, C03.0, C03.1, C03.9-C04.1, C04.8-C05.0, C06.0-C06.2, C06.8, and C06.9), the oropharynx (codes C01.9, C02.4, C05.1, C05.2, C5.8, C5.9, C09.0, C09.1, C09.8-C10.4, C10.8, C10.9, C14.0, C14.2, and C14.8), the hypopharynx (codes C12.9-C13.2, C13.8, and C13.9), and the larynx (codes C32.0- C32.3 and C32.8-C32.9) and histology codes for squamous cell carcinoma (SCC) or its variants (codes 8032, 8050, 8052, 8070-8075, and 8083-8084), and salivary gland cancer (code C07 and variants), and other head and neck cancer variants
• • 11. Stage of diagnosis for HNC (Stages I, II, III, IV) according to the AJCC's TNM stages I-IV
• • 12. Diagnosed with malignant neoplasm of thyroid gland, ICD-10 code: C73, and other thyroid cancer variants
• • 13. Diagnosed with BC using malignant neoplasm of breast ICD-O codes for connective tissue of the breast, codes: C50.0, C50.1, C50.2, C50.3, C50.4, C50.5, C50.6, C50.8, C50.9, and other breast cancer variants.
• • 14. Diagnosed with CC using malignant neoplasm of cervix uteri ICD-O codes: C53.0, C53.1, C53.8, C53.9 and other cervical cancer variants.
• • 15. Diagnosed with CRC using colon and rectum malignant neoplasm ICD-O codes for colon (codes: C18, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9) and rectum (code C20), and other colon and rectum cancer variants.
• • 16. Diagnosed with BLC using malignant neoplasm of ICD-O codes: C67.9 and other bladder cancer varients.
• Inclusion Criteria Confirmed via Baseline Survey:
• 17. Rural and medically underserved, defined as meeting the following criteria:
• • Rural: Resides in a rural county with a RUCC code 4-9 AND,
• • Underserved population who come from counties meeting any of the "health professional shortage areas" OR "Medically Underserved Areas/Populations" AND/OR
• • 18. Uninsured: No health insurance (public or private insurance) AND/OR
• • 19. Underinsured: (c.1) Public insurance (e.g., Medicaid, Medicare Part B exclusive, VA) (c.2) 10% or more of annual income is spent on out-of-pocket medical expenses
• Exclusion Criteria Assessed During Screening:
• • 1. Children under 18 years old
• • 2. Individuals who do not speak English or Spanish
• • 3. Individuals not receiving cancer treatment at UCH (Aurora, Highlands Ranch, UCHealth North, UCHealth Memorial Hospital), San Juan Cancer Center, RMCC-Pueblo, St. Mary's or Parkview Medical Center.
• • 4. Diagnosed with primary cancer other than breast, bladder, cervix, colon, rectum, lung, and/or head-and-neck cancer or other type of cancer not listed in the inclusion criteria.
• • 5. Diagnosed with a type of breast, bladder, cervix, colon, rectum, lung, and/or head-and-neck cancer listed under inclusion criteria but will not be treated at one of the collaborating hospital sites,
• • 6. Has already initiated curative treatment for the current episode of cancer.
• Exclusion Criteria Assessed via Baseline Survey:
• • 7. Individuals from vulnerable populations (e.g., inmates or on probation, homeless\*, and pregnant\*)
• • 8. Decisionally-challenged with cognitive or personality impairment, suicidal ideation or intoxication (alcohol or drugs) at the time of consent or endorsed in baseline survey that interfere with ability to participate in the study.
• • 9. Unable to hear (not including individuals who can hear with an auditory aid).\*
• • 10. Likely inability to track the individual over time (e.g. no permanent address at the time of consent) \*Individuals who become homeless, pregnant, or lose their hearing or permanent address after they have consented and/or assigned to study condition may remain in the study until completion